Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 23, 2023 - Issue 8: Biosimilars
Submit an article Journal homepage
2,674
Views
0
CrossRef citations to date
0
Altmetric
Original Research

GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar

Oliver von Richtera Clinical Development Biopharmaceuticals, Hexal AG (a Sandoz company), Holzkirchen, GermanyCorrespondence[email protected]
View further author information
,
Terry O’Reillyb Celerion, Phoenix, AZ, USAView further author information
,
Davide Guerrieria Clinical Development Biopharmaceuticals, Hexal AG (a Sandoz company), Holzkirchen, GermanyView further author information
,
Jamie Fanc BioPharma Clinical Development, Sandoz Inc, Princeton, NJ, USAView further author information
,
Constanze Feya Clinical Development Biopharmaceuticals, Hexal AG (a Sandoz company), Holzkirchen, GermanyView further author information
,
Steven Schusslerc BioPharma Clinical Development, Sandoz Inc, Princeton, NJ, USAView further author information
,
Fabricio Furland Global Medical Affairs, Biopharmaceuticals, Hexal AG (a Sandoz company), Holzkirchen, GermanyView further author information
&
Lena Lemkea Clinical Development Biopharmaceuticals, Hexal AG (a Sandoz company), Holzkirchen, GermanyView further author information
 show all
Pages 749-758 | Received 03 Aug 2022, Accepted 23 Aug 2022, Published online: 30 Aug 2022

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.